CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Drug-Eluting Stents in the Treatment of Intermediate Lesions
Pooled Analysis From Four Randomized Trials
Jeffrey W. Moses, MD, FACC*,1,*,
Gregg W. Stone, MD, FACC*,2,
Eugenia Nikolsky, MD, PhD, FACC*,
Gary S. Mintz, MD, FACC*,
George Dangas, MD, PhD, FACC*,
Eberhard Grube, MD ,
Stephen G. Ellis, MD, FACC ,3,
Alexandra J. Lansky, MD, FACC*,
Giora Weisz, MD*,
Martin Fahy, MSc*,
Yingbo Na, MSc*,
Mary E. Russell, MD, FACC ,4,
Dennis Donohoe, MD||,5,
Martin B. Leon, MD, FACC*,6 and
Roxana Mehran, MD, FACC*
* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Heart-Center Siegburg, Siegburg, Germany
Cleveland Clinic Foundation, Cleveland, Ohio
Boston Scientific Corp, Natick, Massachusetts
|| Cordis Corp., Warren, New Jersey
Manuscript received September 19, 2005;
revised manuscript received December 23, 2005,
accepted January 9, 2006.
* Reprint requests and correspondence: Dr. Jeffrey W. Moses, Center for Interventional Vascular Therapy, Columbia University Medical Center, 161 Fort Washington Avenue, Irving Pavilion–5th Floor, New York City, New York 10032. (Email: jm2456{at}columbia.edu).
OBJECTIVES: To address the safety and efficacy of drug-eluting stents (DES) in the treatment of intermediate lesions, we performed a pooled analysis of four randomized DES versus bare-metal stent (BMS) trials and assessed outcomes among patients with intermediate lesions.
BACKGROUND: Before the introduction of DES, intermediate coronary lesions were commonly managed based on physiologic or anatomic assessment of lesion severity. The DES may challenge this paradigm.
METHODS: The study population involved 167 of 2,478 randomized patients (6.7%) with intermediate lesions (diameter stenosis <50% [mean 44%] by quantitative coronary angiography) from the Sirolimus-coated Bx Velocity Balloon Expandable Stent in the Treatment of Patients with De Novo Coronary Artery Lesions (SIRIUS), TAXUS-IV, and the First and Second First Use to Underscore Restenosis Reduction with Everolimus (FUTURE-I and -II) trials. End points examined included early (in-hospital and 30-day) and late (1-year) major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis, and follow-up angiographic restenosis.
RESULTS: Patients with intermediate lesions randomized to DES versus BMS had low rates of 30-day MACE (1.1% vs. 4.0% respectively; p = 0.22). At one-year follow-up, patients treated with DES versus BMS had similar rates of cardiac death (0% vs. 2.7%, respectively; p = 0.11) and MI (3.4% vs. 5.4%; p = 0.49) but markedly lower rates of TVR (3.4% vs. 20.3%; p = 0.0004), MACE (5.6% vs. 25.4%; p = 0.0003), and binary angiographic restenosis (1.8% vs. 34.0%; p < 0.0001). No patient in either group developed stent thrombosis.
CONCLUSIONS: Compared with BMS, treatment of intermediate lesions with DES appears safe and results in a marked reduction in clinical and angiographic restenosis. The efficacy of DES may require a reevaluation of current treatment paradigms for intermediate lesions.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent | | DES = drug-eluting stent | | FFR = fractional flow reserve | | IVUS = intravascular ultrasound | | MACE = major adverse cardiac events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | QCA = quantitative coronary angiography | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
S.-J. Park, J.-M. Ahn, and S.-J. Kang
Paradigm Shift to Functional Angioplasty: New Insights for Fractional Flow Reserve- and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention
Circulation,
August 23, 2011;
124(8):
951 - 957.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-W. Nam, H.-J. Yoon, Y.-K. Cho, H.-S. Park, H. Kim, S.-H. Hur, Y.-N. Kim, I.-S. Chung, B.-K. Koo, S.-J. Tahk, et al.
Outcomes of Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease: Fractional Flow Reserve-Guided Versus Intravascular Ultrasound-Guided
J. Am. Coll. Cardiol. Intv.,
August 1, 2010;
3(8):
812 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. H. J. Pijls, W. F. Fearon, P. A. L. Tonino, U. Siebert, F. Ikeno, B. Bornschein, M. van't Veer, V. Klauss, G. Manoharan, T. Engstrom, et al.
Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study
J. Am. Coll. Cardiol.,
July 13, 2010;
56(3):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rodes-Cabau, O. F. Bertrand, E. Larose, J.-P. Dery, S. Rinfret, R. Bagur, G. Proulx, C. M. Nguyen, M. Cote, M.-C. Landcop, et al.
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial
Circulation,
November 17, 2009;
120(20):
1978 - 1986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Parikh and M. A. Costa
Secondary Prevention, the Interventional Way: Prophylactic Drug-Eluting Stents for Nonobstructive Saphenous Vein Graft Disease
Circulation,
November 17, 2009;
120(20):
1940 - 1942.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.-G. Chassot, A. Delabays, and D. R. Spahn
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction
Br. J. Anaesth.,
September 1, 2007;
99(3):
316 - 328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. H.J. Pijls, P. van Schaardenburgh, G. Manoharan, E. Boersma, J.-W. Bech, M. van't Veer, F. Bar, J. Hoorntje, J. Koolen, W. Wijns, et al.
Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis: 5-Year Follow-Up of the DEFER Study
J. Am. Coll. Cardiol.,
May 29, 2007;
49(21):
2105 - 2111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear
Coronary artery stents and non-cardiac surgery
Br. J. Anaesth.,
May 1, 2007;
98(5):
560 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Mintz and N. J. Weissman
Intravascular Ultrasound in the Drug-Eluting Stent Era
J. Am. Coll. Cardiol.,
August 1, 2006;
48(3):
421 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
